Lexicon Pharmaceuticals | LXRX - Cash And Equivalent


Lexicon Pharmaceuticals reported $38.09M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Illumina USD 1.09B 329M Mar/2026
Insmed USD 544.76M 37.42M Jun/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
J&J USD 20.42B 1.27B Jun/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
MacroGenics USD 113.91M 47.39M Jun/2026
MannKind USD 52.93M 95K Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Moderna USD 1.72B 185M Jun/2026
Novartis USD 7.62B 739M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025